# An Open-Label Extension of BPS-MR-PAH-201 in Pulmonary Arterial Hypertension (PAH) Patients

> **NCT00792571** · PHASE2 · COMPLETED · sponsor: **Lung Biotechnology PBC** · enrollment: 18 (actual)

## Conditions studied

- Pulmonary Arterial Hypertension

## Interventions

- **DRUG:** Beraprost Sodium Modified Release

## Key facts

- **NCT ID:** NCT00792571
- **Lead sponsor:** Lung Biotechnology PBC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-02-28
- **Primary completion:** 2013-11-30
- **Final completion:** 2013-11-30
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2019-12-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00792571

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00792571, "An Open-Label Extension of BPS-MR-PAH-201 in Pulmonary Arterial Hypertension (PAH) Patients". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00792571. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*